

Machine Learning Algorithms as an Early Predictor of Alzheimer's disease

Marek Kociński

2024.08.22 IMR




Alzheimer's disease

- Loss of autonomy in day-to-day functioning
- Managing everyday life activities such as:
 - finances,
 - medication,
 - running errands,
 - preparing meals,
 - maintaining interests,
- is one of the criteria differentiating between mild cognitive impairment (MCI) and Alzheimer's disease (AD).



The goal of the project: To find an early predictor(s) of AD



DATA



The ADNI clinical dataset comprises clinical **longitudinal** information about each subject including:

- recruitment,
- demographics,
- physical examinations,
- and cognitive assessment data.

| STUDY CHARACTERISTICS | ADNI-1 | ADNI-GO (Grand Opportunities) | ADNI-2 | ADNI-3 |
|-----------------------|--|---|--|--|
| Primary goal | Develop biomarkers as outcome measures for clinical trials | Examine biomarkers in earlier stages of disease | Develop biomarkers as predictors of cognitive decline, and as outcome measures | Study the use of tau PET and functional imaging techniques in clinical trials |
| Funding | \$40 million federal (NIA), \$27 million industry and foundation | \$24 million American Recovery Act funds | \$40 million federal (NIA), \$27 million industry and foundation | \$40 million federal (NIA), up to \$20 million industry and foundation |
| Duration/start date | 5 years/October 2004 | 2 years/September 2009 | 5 years/September 2011 | 5 years/September 2016 |
| Cohort | 200 elderly controls 400 MCI 200 AD | Existing ADNI-1 + 200 early MCI | Existing ADNI-1 and ADNI-GO + 150 elderly controls 100 early MCI 150 late MCI 150 AD | Existing ADNI-1, ADNI-GO, ADNI-2 + 133 elderly controls 151 MCI 87 AD |



Citation Impact

3.921 - 2-year Impact Factor

4.878 - 5-year Impact Factor

1.758 - Source Normalized

Impact per Paper (SNIP)

1.414 - SCImago Journal Rank


(SJR)

Functional activity level reported by an informant is an early predictor of Alzheimer's disease.

Alexandra Vik^{1*}, Marek Kocinski^{1,3}, Ingrid Rye², Astri J Lundervold², Alexander S Lundervold^{1,4} and for the Alzheimer's Disease Neuroimaging Initiative⁵
Vik et al.

Loss of autonomy in day-to-day functioning may be noticed by relatives subtle changes in ordinary life situations long before these changes are given medical diagnosis.

In this study we ask if: even such subtle changes should be given weight as an early predictor of AD, by including report scales like the functional activity questionnaire (FAQ).



Data balance for: gender, age bins, age and length of participation

Methods and Results

| Demographics | sMCI (360) | cAD (320) |
|---|-----------------------|-----------------------|
| | Train (285)/Test (75) | Train (255)/Test (65) |
| Sex (F:M) | 114:171/32:43 | 99:156/25:40 |
| Age at inclusion [years]: mean (SD) | 73.9 (7.4)/72.7(7.3) | 73.9 (7.7)/73.9 (6.9) |
| Age at inclusion [years]: range | 55-91/57.8-87.8 | 55.2-88.3/55-88.4 |
| Education [years]: mean (SD) | 15.8 (2.9)/16.2(2.9) | 15.8 (2.9)/16.2(2.9) |
| Participation length [years]: mean (SD) | 4.6 (2.8)/4.5(2.7) | 5.0 (2.7)/5.5(2.8) |

Demographics of the included subsample extracted from the ADNI cohort.
sMCI – stable mild cognitive impairment, cAD – converting Alzheimer's Disease

Eleven neurocognitive features were used as input in a **Random Forest binary classifier** (sMCI vs. cAD) model

Results for RF classifier:

accuracy = 73%

| | | Confusion Matrix | |
|-------------------------|------|--|--|
| | | sMCI | cAD |
| Observed (true) Outcome | sMCI | N = 58 (41%-TN) Age: 72, Sex: 25:33 FAQ ≥ 9 : 3, 1.8 (3.7) GDS ≥ 5 : 3, 1.9 (1.4) RAVLT-lm: 39.1 (8.7) TMTB: 93 (36) HC: 0.0046 LVV: 0.023 | N = 17 (12%-FP) Age: 76, Sex: 7:10 FAQ ≥ 9 : 3, 4.4 (4.8) GDS ≥ 5 : 0, 1.6 (0.9) RAVLT-lm: 29.1 (6.2) TMTB: 131 (56) HC: 0.0037 LVV: 0.030 |
| | cAD | N = 20 (14%-FN) Age: 74, Sex: 8:12 FAQ ≥ 9 : 0, 1.8 (2.3) GDS ≥ 5 : 0, 1.5 (1.2) RAVLT-lm: 37.2 (6.7) TMTB: 115 (82) HC: 0.0045 LVV: 0.025 | N = 45 (32%-TP) Age: 74, Sex: 17:28 FAQ ≥ 9 : 10, 5.7 (4.8) GDS ≥ 5 : 0, 1.4 (1.2) RAVLT-lm: 27.8 (4.8) TMTB: 140 (80) HC: 0.0038 LVV: 0.030 |
| | | sMCI | cAD |
| | | Predicted Outcome | |

Predicting conversion to Alzheimer’s Disease in individuals with Mild Cognitive Impairment using clinically transferable features

Ingrid Rye^{1,+}, Alexandra Vik^{2,+}, Marek Kocinski^{2,3,4,+}, Alexander S. Lundervold^{2,5}, Astri J. Lundervold¹, and for the Alzheimer’s Disease Neuroimaging Initiative^{**}


- Journal metrics 2021
- 2-year impact factor: 4.380
 - 5-year impact factor: 5.134
 - Immediacy index: 0.783
 - Eigenfactor® score: 1.23250
 - Article influence score: 1.285
 - 2 year median: 3

Longitudinal data that identify two groups of patients who were diagnosed with MCI at a **baseline clinical examination**: one group including patients who were diagnosed with AD and one group retaining their MCI diagnosis during the observation period.

Selected features included **demographic data**, **information from neuropsychological** and **MRI** examinations and **genetic information** about APOE status.

- We train two different supervised learning algorithms:
- an ensemble-based model constructed by combining five different models
 - a Random Forest (RF) model

Confusion matrix for Random Forest model’s prediction on test set.




Results for RF classifier:

accuracy = 66%

| | sMCI (N = 357) Mean (SD) | cAD (N = 321) Mean (SD) |
|---------------------|---------------------------------|---------------------------------|
| Demographics | | |
| Age | 73.1 (7.45) | 73.9 (7.11) |
| Gender (%F) | 41.2 | 38.9 |
| Cognitive Function | | |
| RAVLT-Im | 36.9 (10.5) | 29.3 (7.7) |
| RAVLT-Delay | 4.88 (3.93) | 2.05 (2.67) |
| RAVLT-Recog | 11.26 (3.16) | 9.42 (3.56) |
| TMTA | 39.2 (15.6) | 44.7 (21.5) |
| TMTB | 108.1 (56.9) | 133.8 (73.9) |
| CFT animals | 17.8 (5.17) | 15.8 (4.75) |
| GDS: mean (SD) | 1.71 (1.44) | 1.65 (1.38) |
| ANART Total errors | 12.9 (9.3) | 13.3 (9.6) |
| Biological measures | | |
| Hippocampus volume | 0.00451 (7.6*10 ⁻⁴) | 0.00398 (6.8*10 ⁻⁴) |
| APOE (%positive) | 42.3 | 64.2 |

Demographics of the included subsample extracted from the ADNI cohort.
sMCI – stable mild cognitive impairment, cAD – converting Alzheimer’s Disease

2D and 3D U-Nets for skull stripping in large and heterogeneous set of head MRI using *fastai**




* - Sathiesh's presentation "Deep learning for medical image analysis: *fastai* + *MONAI*"; tomorrow 11:30-11:45

Data sets:

- ADNI
- AIBL
- IXI
- PPMI
- SLIM
- Calgary-Campinas
- SALD



Training test: 2791 3D images
Test sets: 934 + 561 3D images





Dice = 0.978
Jaccard = 0.957

Violin plot of the Dice scores obtained by our models on the test dataset


Assessing kidney function from DCE-MRI




Assessing kidney function from DCE-MRI



Manual labelling



Automatic aorta segmentation



Time series extraction and modeling